Cefepime/enmetazobactam for invasive infections caused by extended-spectrum beta-lactamase-producing Enterobacterales: a real-world case series.

We present our retrospective case series of eight patients with either bloodstream infection, pneumonia or complicated intra-abdominal infection caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) treated with cefepime/enmetazobactam. Treatment failure and 30-day all-cause mortality occurred in one patient each. Cefepime/enmetazobactam showed favorable clinical results and may represent a carbapenem-sparing treatment option in selected patients with invasive ESBL-E infections. Real-world data remain limited and further studies are needed to specify the most suitable patient population.